RT Journal Article
SR Electronic
T1 PSMA Ligands for PET Imaging of Prostate Cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1545
OP 1552
DO 10.2967/jnumed.117.191031
VO 58
IS 10
A1 Sarah M. Schwarzenboeck
A1 Isabel Rauscher
A1 Christina Bluemel
A1 Wolfgang P. Fendler
A1 Steven P. Rowe
A1 Martin G. Pomper
A1 Ali Asfhar-Oromieh
A1 Ken Herrmann
A1 Matthias Eiber
YR 2017
UL http://jnm.snmjournals.org/content/58/10/1545.abstract
AB Targeting the prostate-specific membrane antigen (PSMA) with 68Ga-labeled and 18F-labeled PET agents has become increasingly important in recent years. Imaging of biochemically recurrent prostate cancer has been established as a widely accepted clinical indication for PSMA ligand PET/CT in many parts of the world because of the results of multiple, primarily retrospective, studies that indicate superior detection efficacy compared with standard-of-care imaging. For high-risk primary prostate cancer, evidence is growing that this modality significantly aids in the detection of otherwise occult nodal and bone metastases. For both clinical indications in recurrent as well as in primary prostate cancer, preliminary data demonstrate a substantial impact on clinical management. Emerging data imply that intraprostatic tumor localization, therapy stratification, and treatment monitoring of advanced disease in specific clinical situations might become future indications. Current criteria for image reporting of PSMA ligand PET are evolving given the expanding body of literature on physiologic and pathologic uptake patterns and pitfalls. This article intends to give an educational overview on the current status of PSMA ligand PET imaging, including imaging procedure and interpretation, clinical indications, diagnostic potential, and impact on treatment planning.